Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company developing novel small molecule drugs to treat cancer, closed a $23M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, The Vertical Group and Amgen Ventures.

Core Essence Orthopaedics (Fort Washington, PA) a commercial-stage medical device company focused on MIS arthroscopic and endoscopic procedures involving soft tissue and skeletal repair, closed a $11.5M Series B financing. Participants include Baird Venture Partners, NewSpring Health Capital and Robin Hood Ventures.

BioNanomatrix (Philadelphia, PA) commercial-stage developer of a nanochannel array chip, single-molecule imaging and analysis platform, closed a $23.3M Series B financing. Participants include Domain Associates, Gund Investment Corp., Battelle Ventures, Innovation Valley Partners and KT Venture Group.

NeoGraft Technologies (Pittsburgh, PA) a development-stage medical device company focused on coronary artery disease, closed a $3M Series B financing. Participants were not identified.

Small Bone Innovations (Morrisville, PA) a commercial-stage a small bone and joint device company focused on arthroplasty, fixation, trauma and biologic solutions, closed a $15M Series F financing. Participants have included 3i Group, NGN Capital, Trevi Health Ventures, Viscogliosi Brothers, Vollin Holdings and The Family Office Co.

ClearCount Medical Solutions (Pittsburgh, PA) a commercial-stage company focused on patient safety with RFID tagged surgical smart sponges for surgical reconciliation and operational efficiency, closed a $5M Series B financing. Participants include Draper Triangle Ventures and Draper Fisher Jurvetson.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $5M Series C financing, bringing the total round to $37M. Participants include Pfizer Venture Investments, Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, […]

Gemin X Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company focused on chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $8M Series E financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.

Health Market Science (King of Prussia, PA) a commercial-stage biopharma and healthcare data and analytics provider, closed a $6.1M Series B financing. Participants include Cross Atlantic Capital Partners and Edison Venture Fund.

TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Molecular Detection (Wayne, PA) a commercial-stage molecular diagnostics company focused on MRSA detection, closed a $1.4M Series C financing, bringing the total round to $4.7M. Participants include MentorTech Ventures.

Promedior (Malvern, PA) a clinical-stage biopharmaceutical company focused on inflammation and fibrotic disease, closed a $12M Series C financing. Participants include Forbion Capital Partners, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners and Easton Capital.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...